Paul Witting
Professor
Pathology
University of Sydney
Australia
Biography
Dr Paul Witting is an Associate Professor in the Discipline of Pathology at The University of Sydney and a career biomedical researcher. He has held ARC (2003-2007) and National Heart Foundation Fellowships (1999-2001) that financed post-doctoral terms at the ANZAC Research Institute and University of British Columbia (Canada), respectively. He has a proven track record in the field of bio-medical chemistry publishing 105 peer-reviewed papers (mean impact factor (IF) ~4.9 with >90% appearing in international journals); 6-book chapters; 12-invited review articles and one International Patent. Publications by Witting and his co-workers have been acknowledged with 3944 citations (mean citation/publication ~35 yielding an H-index ~34). He has been awarded ~A$11.2 Million in competitive funding from agencies including the ARC, NHF, Wellcome Trust, NHMRC Equipment Grants, The Ramaciotti, Bushell and CASS Foundations, Eli Lilly Diabetes Foundation, Servier International, Diabetes Australia Research Trust and the University of Sydney Strategic Development Grants Scheme.
Research Interest
Dr Witting's research interest is in exploring the relationship between oxidative stress and the evolution of tissue damage in the acute setting of stroke and myocardial infarct. He is also collaborating with clinicians in the Concord Hospital Burns Unit as he examines the relationship between severe burn, muscle myolysis and acute renal failure.
Publications
-
Witting, P. (2016). Measuring redox-active species in cells and tissues. Focus on "A case of mistaken identity: are reactive oxygen species actually reactive sulfide species?". American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 310(7), R547-R548.
-
Dennis, J., Witting, P. (2017). Protective Role for Antioxidants in Acute Kidney Disease. Nutrients, 9(7), 1-25.
-
Gotsbacher, M., Telfer, T., Witting, P., Double, K., Finkelstein, D., Codd, R. (2017). Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease. Metallomics, 9(7), 852-864.